In contrast, G47Δ, a third-generation HSV-1 derivative, has received conditional approval in Japan for GBM, demonstrating an 84.2% one-year survival rate and robust tumor-infiltrating CD4+/CD8+ T-cell responses (234). Here, CD8A is linked to glioblastoma.